In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Drug Discovery for Remission of Chronic Kidney Disease

Drug Discovery for Remission of Chronic Kidney Disease

Friday, September 25, 2020, 8:30 AM - 5:00 PM

7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Thirty million Americans have chronic kidney disease (CKD) and over 600,000 are currently living with end stage kidney disease (ESKD), requiring dialysis or kidney transplantation to sustain their lives. However, the great majority of patients living with ESKD do not have access to kidney transplantation due to the scarcity of donor organs. Moreover, there have been few advances in effective treatments for patients living with kidney disease in the past fifty years.

This symposium will highlight the latest research on the physiological and genetic mechanisms underlying CKD, as well as novel imaging techniques and emerging biomarkers that promise improved detection and characterization of the disease. There will also be discussion of recent progress and remaining hurdles for novel ESKD treatment strategies, including kidney xenotranplantation.

Registration

Member
By 08/14/2020
$90
After 08/14/2020
$130
Nonmember Academia, Faculty, etc.
By 08/14/2020
$180
After 08/14/2020
$260
Nonmember Corporate, Other
By 08/14/2020
$250
After 08/14/2020
$350
Nonmember Not for Profit
By 08/14/2020
$180
After 08/14/2020
$260
Nonmember Student, Undergrad, Grad, Fellow
By 08/14/2020
$100
After 08/14/2020
$145
Member Student, Post-Doc, Fellow
By 08/14/2020
$50
After 08/14/2020
$70

Keynote Speaker

Jonathan Himmelfarb, MD

University of Washington

Speakers

Kevin Bennett, PhD
Kevin Bennett, PhD

Washington University in St. Louis

Xunrong Luo
Xunrong Luo, MD, PhD

Duke University School of Medicine

Benjamin Freedman
Benjamin Freedman, PhD

University of Washington

Monika Niewczas
Monika Niewczas, MD, PhD, MPH

Joslin Diabetes Center, Harvard Medical School

Ali Gharavi
Ali Gharavi, MD

Columbia University Irving Medical Center

Karin Hehenberger, MD, PhD
Karin Hehenberger, MD, PhD

Lyfebulb

Katalin Susztak, MD, PhD
Katalin Susztak, MD, PhD

Perelman School of Medicine, University of Pennsylvania

Katherine Tuttle
Katherine Tuttle, MD

Providence Medical Research Center, University of Washington

Scientific Organizing Committee

Matthew D. Breyer, MD

Janssen Pharmaceuticals

Kishor Devalaraja-Narashimha, DVM, PhD

Regeneron Pharmaceuticals

Susan Quaggin, MD

Northwestern University

Michael Ross, MD

Albert Einstein College of Medicine

Joseph Vassalotti, MD

National Kidney Foundation

Sara Donnelly, PhD

New York Academy of Sciences

Sonya Dougal, PhD

New York Academy of Sciences